Pharmacokinetics of Terazosin Enantiomers in Healthy Chinese Male Subjects

ABSTRACT The purpose of this study was to elucidate the pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. After a single oral dose of 2‐mg terazosin, the plasma concentrations of terazosin enantiomers were measured over the course of 48 h in 12 healthy subjects. The plasma...

Full description

Saved in:
Bibliographic Details
Published inChirality (New York, N.Y.) Vol. 24; no. 12; pp. 1047 - 1050
Main Authors Liu, Man, Zhang, Dan, Yang, Man, Zhao, Ting, Wang, Xiaolin, Zhang, Yanan, Han, Jing, Liu, Huichen
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.12.2012
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0899-0042
1520-636X
1520-636X
DOI10.1002/chir.22095

Cover

More Information
Summary:ABSTRACT The purpose of this study was to elucidate the pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. After a single oral dose of 2‐mg terazosin, the plasma concentrations of terazosin enantiomers were measured over the course of 48 h in 12 healthy subjects. The plasma concentrations of (+)‐(R)‐terazosin at all time points were higher than those of (−)‐(S)‐terazosin. The area under the plasma concentration–time curve (AUC0–∞) and maximum plasma concentration of (+)‐(R)‐terazosin were significantly greater than those of the (−)‐(S)‐terazosin (P < 0.01, respectively). The R/S ratio of AUC0–∞ of terazosin was 1.68. For the first time, it was proven that the pharmacokinetics of terazosin was stereoselective in healthy Chinese male subjects. Chirality 24:1047–1050, 2012. © 2012 Wiley Periodicals, Inc.
Bibliography:This work was supported by the Daicel Chiral Technologies (China) Co., Ltd
ark:/67375/WNG-RW2HJKLF-Z
ArticleID:CHIR22095
istex:1CEE97B8DE9D45FBA52ED7313F85083212081769
ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Feature-2
ISSN:0899-0042
1520-636X
1520-636X
DOI:10.1002/chir.22095